Quadrucept Bio. Ltd.

Founded by Kymab's former leadership team (acquired by Sanofi in 2021) Quadrucept's QUAD Technology Empowers the Next-Generation of Antibody-based Drugs:- - Super Antagonists: From new or existing Fab or VHH domains - Superior “Receptor Bodies”: High avidity receptor-Fc fusion decoy molecules - Potent Antibody Agonists: Multivalent Fab/VHH receptor clustering - Improved Target Selectivity: Tetravalent low-affinity high-avidity binding - Pioneering Bi-Specifics: Flexible formats tailored for every need - Fc-Multi-valency: Enabling “best-in-class” half-life extension - “One-Two Punch” ADCs: Avidity-driven targeting-Greater payload capacity - Simplicity: Highly efficient self-assembly of monomeric building blocks - Standard Manufacturing: High expression, stability, drug-like properties - Broad and Early Patent Estate: First to the field – All therapeutic targets